Why GW Pharmaceuticals (GWPH) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- GW Pharmaceuticals  (GWPH) surged to a 52-week high of $89.48 on Tuesday after the British biotech company reported positive safety and efficacy data from its epilepsy treatment drug Epidiolex.

The data from an efficacy group of 27 patients showed those who took the drug displayed a 44% median overall reduction in seizure frequency over 12 weeks. A total of 22% of patients had a 90% reduction and 15% had no seizures whatsoever. The data from a safety group of 62 patients showed at least one adverse event occurred in 81% of patients, though 80% of those events were mild to moderate.

The stock was up 13.93% to $88.01 at 12:58 p.m. More than 2.5 million shares had changed hands by that point, which surpassed the average volume of 876,645.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

GWPH Price Chart

GWPH Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Snap-On, Teekay Shipping, FLIR Systems, GW Pharmaceuticals: 'Mad Money' Lightning Round

Time to Raise Some Cash: Cramer's 'Mad Money' Recap (Tuesday 8/1/17)